Page 11 - Norgine Annual Report 2017
P. 11

Looking




 Forward







 2018 is a year of acceleration for Norgine.
 Norgine will continue to focus on maximising
 the sales of its existing products and
 integrate the Merus Labs International                     Executive
 Inc. business while also pursuing new
 opportunities to diversify its revenue base
 and to bring transformative products to                    Team
 patients.


 In 2018, we anticipate to further launch
 ®
 PLENVU  and LYMPHOSEEK  through our
 ®
 infrastructure and we are also anticipating
                                            Peter Stein
 ®
 FDA approval of PLENVU .
                                       Chief Executive Officer



                                     Christopher Bath                              Peter Martin
                                        Chief Financial Officer                    Chief Operating Officer






                                 Kenneth Scrimgeour                                Paul Pay
                                     Chief Commercial Officer                      Chief Business Development Officer






                                  Dr Alastair Benbow                               Sheila Hopkins
                                       Chief Development and                       Chief Legal Officer
                                              Medical Officer





                                             Tara Barry                            Philippe Caroff
                                Chief Human Resources Officer                      Chief Manufacturing Officer






 9                                                                                                               10
   6   7   8   9   10   11   12